Answers are grounded in this paper and cite their sources.
Platelet-derived extracellular vesicles (PDEVs) from activated platelets possess a shifted biomolecular profile and enhanced procoagulant activity. However, the specific EV proteome and surface antigens characterizing these vesicles in acute thrombotic events remain poorly defined. We aimed to identify a thromboinflammatory PDEV surface signature and evaluate its diagnostic potential in deep vein thrombosis (DVT). PDEVs from control or TRAP6-activated washed platelets were analysed by mass spectrometry (MS). Candidate protein markers were validated on the surface of washed platelets PDEVs and plasma EVs from DVT patients, symptomatic non-DVT patients, and healthy controls using an in-house immunocapture bead-based flow cytometry assay. Platelet activation enriched 129 proteins in the PDEV proteome, primarily mediators of coagulation and inflammation. While MS identified high levels of vWF and Factor V, flow cytometry confirmed that CD41, CD62P, CCL5, and CD9 are specifically enriched on the PDEV surface. An integrated multi-marker panel (CD41, CD9, CD151, PF4, FV, CD62P) successfully discriminated DVT patients from healthy controls, but not between DVT and symptomatic non-DVT patients. In conclusion, activation reconfigures the EV proteome and surface into a distinct thromboinflammatory signature. While this signature captures systemic platelet activation in symptomatic patients, further refinement is required to achieve clot-specific diagnostic utility.
No takes yet. Share an insight, caveat, or question.
Guerreiro et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: